Search
Close this search box.

COPD

D9180C00004

STUDY OUTLINE

This study will be investigating whether a treatment called tozorakimab could help manage COPD exacerbations (often called flare-ups, where COPD symptoms get worse) in patients who are currently receiving treatment for COPD. If successful, the findings from this will help in the development of future treatments for individuals with COPD.

In the research study you will either be receiving tozorakimab or placebo every month as a subcutaneous injection given at site. You will continue your usual COPD medications.

To find out if this trial is suitable for you, please register below, or contact our Clinical Trials Team on 6151 0813 or email clinicaltrials@resphealth.uwa.edu.au.

ELIGIBILITY & REQUIREMENTS

  • At least 40 years of age
  • Confirmed diagnosis of COPD for at least 1 year
  • Have had at least 2 COPD exacerbations requiring treatment with oral steroids and/or antibiotics OR at least 1 COPD exacerbation requiring hospitalisation within the past 12 months
  • Current or former cigarette smoker
  • Taking inhaled medication(s) (puffers) to treat your COPD
  • There are additional eligibility requirements to enrol in this study

WHAT'S INVOLVED

  • The trial will run for a minimum of 52 weeks of treatment
  • A minimum of 16 clinic visits to the Institute for Respiratory Health at QEII Medical Centre, Nedlands
  • A full health check by our doctors and nurses
  • Reimbursement for travel expenses
  • Personalised health care with our doctors and nurses

PRINCIPAL INVESTIGATOR

Dr Sanjay Ramakrishnan (Nedlands)

REGISTER YOUR INTEREST TODAY

* indicates required
Scroll to Top